Keita Kirito

机构：University of Yamanashi Hospital, University of Yamanashi · ORCID：0000-0001-5682-2132

发表论文 229 篇 · 总被引 3631 次 · h-index 35

代表论文

• Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study (2025 · The Lancet Haematology · 被引 9)
• Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms (2025 · Current Hematologic Malignancy Reports · 被引 4)
• Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial. (2025 · Journal of Clinical Oncology · 被引 4)
• A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia (2025 · International Journal of Hematology · 被引 4)
• Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis (2026 · Blood Advances · 被引 2)
• Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST (2025 · International Journal of Hematology · 被引 2)